Passive absorption of fentanyl from the fentanyl HCl iontophoretic transdermal system

By Sathyan Gayatri   Phipps Brad   Gupta Suneel K.  

Current Medical Research and Opinion, Vol. 25, Iss. 2, 2009-02 ,pp. : 363-366

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain

By Clark A.J.   Ahmedzai S.H.   Allan L.G.   Camacho F.   Horbay G.L.A.   Richarz U.   Simpson K.  

Current Medical Research and Opinion, Vol. 20, Iss. 9, 2004-09 ,pp. : 1419-1428

Informa Healthcare

Access to resources Recommend Favorite

Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine

By Radbruch Lukas   Lehmann K.   Gockel H.-H.   Neighbors D.   Nuyts G.  

The European Journal of Health Economics, Vol. 3, Iss. 2, 2002-06 ,pp. : 111-119

Springer Publishing Company

Access to resources Recommend Favorite

A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain

By Otis James   Rothman Margaret  

Current Medical Research and Opinion, Vol. 22, Iss. 8, 2006-08 ,pp. : 1493-1501

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of a New Fentanyl Tape with a Novel Delivery System of Transdermal Matrix Patches in Patients with Cancer Pain

By  

Oncology, Vol. 86, Iss. 1, 2013-12 ,pp. : 10-15

Karger

Access to resources Recommend Favorite